-transparent.png){kind=logo}
Three courses of intermediate dose methotrexate, 500 mg/m2 at three weekly intervals have been used as part of sanctuary therapy to 95 out of 112 children with acute lymphocytic leukaemia in Norway in the period August 1975 to December 1979. Eight doses of MTX IT were also used for CNS prophylaxis, the first dose was given on the day of admission. As of July 1, 1980, 75 out of 95 (79%) were still in CCR for a median of 36 months (6-57 months).
Related Publications
P J Moe, and
M Seip, and
P H Finne
January 1979,
Haematology and blood transfusion,
P J Moe, and
M Seip, and
P H Finne
January 1985,
Sangre,
P J Moe, and
M Seip, and
P H Finne
January 1981,
Haematology and blood transfusion,
P J Moe, and
M Seip, and
P H Finne
January 1984,
Indian journal of cancer,
P J Moe, and
M Seip, and
P H Finne
April 1986,
European journal of pediatrics,
P J Moe, and
M Seip, and
P H Finne
September 1980,
Indian journal of cancer,
P J Moe, and
M Seip, and
P H Finne
November 1982,
Drug intelligence & clinical pharmacy,
P J Moe, and
M Seip, and
P H Finne
December 1983,
Blut,
P J Moe, and
M Seip, and
P H Finne
May 1981,
The Medical journal of Australia,
P J Moe, and
M Seip, and
P H Finne
July 1977,
Cancer treatment reports,
